Eculizumab therapy leads to rapid resolution of thrombocytopenia in atypical hemolytic uremic syndrome

Han Mou Tsai, Elizabeth Kuo

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Eculizumab is highly effective in controlling complement activation in patients with the atypical hemolytic uremic syndrome (aHUS). However, the course of responses to the treatment is not well understood. We reviewed the responses to eculizumab therapy for aHUS. The results show that, in patients with aHUS, eculizumab therapy, when not accompanied with concurrent plasma exchange therapy, led to steady increase in the platelet count and improvement in extra-renal complications within 3 days. By day 7, the platelet count was normal in 15 of 17 cases. The resolution of hemolytic anemia and improvement in renal function were less predictable and were not apparent for weeks to months in two patients. The swift response in the platelet counts was only observed in one of five cases who received concurrent plasma exchange therapy and was not observed in a case of TMA due to gemcitabine/carboplatin. In summary, eculizumab leads to rapid increase in the platelet counts and resolution of extrarenal symptoms in patients with aHUS. Concurrent plasma exchange greatly impedes the response of aHUS to eculizumab therapy. Eculizumab is ineffective for gemcitabine/carboplatin associated TMA.

Original languageEnglish (US)
Article number295323
JournalAdvances in Hematology
Volume2014
DOIs
StatePublished - 2014

Fingerprint

Thrombocytopenia
gemcitabine
Platelet Count
Plasma Exchange
Carboplatin
Therapeutics
Kidney
Complement Activation
Hemolytic Anemia
eculizumab
Atypical Hemolytic Uremic Syndrome

ASJC Scopus subject areas

  • Hematology

Cite this

Eculizumab therapy leads to rapid resolution of thrombocytopenia in atypical hemolytic uremic syndrome. / Tsai, Han Mou; Kuo, Elizabeth.

In: Advances in Hematology, Vol. 2014, 295323, 2014.

Research output: Contribution to journalArticle

@article{5845e7562f784bc3974ce80a09bdfb99,
title = "Eculizumab therapy leads to rapid resolution of thrombocytopenia in atypical hemolytic uremic syndrome",
abstract = "Eculizumab is highly effective in controlling complement activation in patients with the atypical hemolytic uremic syndrome (aHUS). However, the course of responses to the treatment is not well understood. We reviewed the responses to eculizumab therapy for aHUS. The results show that, in patients with aHUS, eculizumab therapy, when not accompanied with concurrent plasma exchange therapy, led to steady increase in the platelet count and improvement in extra-renal complications within 3 days. By day 7, the platelet count was normal in 15 of 17 cases. The resolution of hemolytic anemia and improvement in renal function were less predictable and were not apparent for weeks to months in two patients. The swift response in the platelet counts was only observed in one of five cases who received concurrent plasma exchange therapy and was not observed in a case of TMA due to gemcitabine/carboplatin. In summary, eculizumab leads to rapid increase in the platelet counts and resolution of extrarenal symptoms in patients with aHUS. Concurrent plasma exchange greatly impedes the response of aHUS to eculizumab therapy. Eculizumab is ineffective for gemcitabine/carboplatin associated TMA.",
author = "Tsai, {Han Mou} and Elizabeth Kuo",
year = "2014",
doi = "10.1155/2014/295323",
language = "English (US)",
volume = "2014",
journal = "Advances in Hematology",
issn = "1687-9104",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Eculizumab therapy leads to rapid resolution of thrombocytopenia in atypical hemolytic uremic syndrome

AU - Tsai, Han Mou

AU - Kuo, Elizabeth

PY - 2014

Y1 - 2014

N2 - Eculizumab is highly effective in controlling complement activation in patients with the atypical hemolytic uremic syndrome (aHUS). However, the course of responses to the treatment is not well understood. We reviewed the responses to eculizumab therapy for aHUS. The results show that, in patients with aHUS, eculizumab therapy, when not accompanied with concurrent plasma exchange therapy, led to steady increase in the platelet count and improvement in extra-renal complications within 3 days. By day 7, the platelet count was normal in 15 of 17 cases. The resolution of hemolytic anemia and improvement in renal function were less predictable and were not apparent for weeks to months in two patients. The swift response in the platelet counts was only observed in one of five cases who received concurrent plasma exchange therapy and was not observed in a case of TMA due to gemcitabine/carboplatin. In summary, eculizumab leads to rapid increase in the platelet counts and resolution of extrarenal symptoms in patients with aHUS. Concurrent plasma exchange greatly impedes the response of aHUS to eculizumab therapy. Eculizumab is ineffective for gemcitabine/carboplatin associated TMA.

AB - Eculizumab is highly effective in controlling complement activation in patients with the atypical hemolytic uremic syndrome (aHUS). However, the course of responses to the treatment is not well understood. We reviewed the responses to eculizumab therapy for aHUS. The results show that, in patients with aHUS, eculizumab therapy, when not accompanied with concurrent plasma exchange therapy, led to steady increase in the platelet count and improvement in extra-renal complications within 3 days. By day 7, the platelet count was normal in 15 of 17 cases. The resolution of hemolytic anemia and improvement in renal function were less predictable and were not apparent for weeks to months in two patients. The swift response in the platelet counts was only observed in one of five cases who received concurrent plasma exchange therapy and was not observed in a case of TMA due to gemcitabine/carboplatin. In summary, eculizumab leads to rapid increase in the platelet counts and resolution of extrarenal symptoms in patients with aHUS. Concurrent plasma exchange greatly impedes the response of aHUS to eculizumab therapy. Eculizumab is ineffective for gemcitabine/carboplatin associated TMA.

UR - http://www.scopus.com/inward/record.url?scp=84911455706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911455706&partnerID=8YFLogxK

U2 - 10.1155/2014/295323

DO - 10.1155/2014/295323

M3 - Article

C2 - 25400666

AN - SCOPUS:84911455706

VL - 2014

JO - Advances in Hematology

JF - Advances in Hematology

SN - 1687-9104

M1 - 295323

ER -